ARKA regulatory standing
How ARKA operates on a first-party AIIE standard, tracks the CMS Appropriate Use Criteria Program, and positions for reinstatement — with cited federal sources.
Licensing posture
ARKA operates on a first-party AIIE standard with no third-party criteria license in the live data path. Scoring draws on peer-reviewed clinical literature, the CMS Appropriate Use Criteria Program structure established by PAMA §218(b), and the RAND/UCLA Appropriateness Method for the 1–9 scale semantics — not on embedded or transcribed proprietary criteria tables.
ARKA's AIIE engine is designed to operate independently of any single criteria licensor — drawing on peer-reviewed clinical literature, CMS Appropriate Use Criteria Program standards (PAMA §218(b)), and first-party machine-learning validation.
Methodology detail: AIIE Methodology & Evidence Basis · Evidence Methodology Dossier
CMS Appropriate Use Criteria Program — current status
The posture below reflects the latest human- or system-confirmed snapshot from CMS and Federal Register sources. Automated monitoring may propose changes; an admin confirms reinstatement or activation with a citation.
What this means for buyers
- No CDSM consultation is required on Medicare fee-for-service claims while the program is paused.
- ARKA already meets the program's clinical-standard intent via the first-party AIIE engine and peer-reviewed evidence register.
- If CMS reinstates the mandate, ARKA is positioned to re-qualify as a CDSM-aligned mechanism at point of order.
Official references
Federal and CMS primary sources for the AUC program and related interoperability rules. All links open in a new tab.